Invasive fungal disease

[Guest guest]

European Organization for Research and Treatment of Cancer/Invasive

Fungal Infections ative Group and the National Institute of

Allergy and Infectious Diseases Mycoses Study Group

Anyone know anything about the group above?

The category of proven invasive fungal disease can apply to any

patient, regardless of whether the patient is immunocompromised, This

is stated in the article below.... (Haven't we been saying this since

we all got ill?)

Revised Definitions of Invasive Fungal Disease from the European

Organization for Research and Treatment of Cancer/Invasive Fungal

Infections ative Group and the National Institute of Allergy and

Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

[My paper] Ben De Pauw, J Walsh, J Donnelly, A

s, E , Thierry Calandra, G Pappas, Johan

Maertens, Olivier Lortholary, Carol A Kauffman, W Denning,

F , Georg Maschmeyer, Jacques Bille, E

Dismukes, Raoul Herbrecht, W Hope, C Kibbler, Bart

Jan Kullberg, Kieren A Marr, Muñoz, C Odds, R

Perfect, Restrepo, Markus Ruhnke, Brahm H Segal, Jack D Sobel,

Tania C Sorrell, Claudio Viscoli, R Wingard, Theoklis Zaoutis,

E

Background. @nbsp; Invasive fungal diseases are important causes of

morbidity and mortality. Clarity and uniformity in defining these

infections are important factors in improving the quality of clinical

studies. A standard set of definitions strengthens the consistency and

reproducibility of such studies. Methods. @nbsp; After the

introduction of the original European Organization for Research and

Treatment of Cancer/Invasive Fungal Infections ative Group and

the National Institute of Allergy and Infectious Diseases Mycoses

Study Group (EORTC/MSG) Consensus Group definitions, advances in

diagnostic technology and the recognition of areas in need of

improvement led to a revision of this document. The revision process

started with a meeting of participants in 2003, to decide on the

process and to draft the proposal. This was followed by several rounds

of consultation until a final draft was approved in 2005. This was

made available for 6 months to allow public comment, and then the

manuscript was prepared and approved. Results. @nbsp; The revised

definitions retain the original classifications of " proven, "

" probable, " and " possible " invasive fungal disease, but the definition

of " probable " has been expanded, whereas the scope of the category

" possible " has been diminished. The category of proven invasive fungal

disease can apply to any patient, regardless of whether the patient is

immunocompromised, whereas the probable and possible categories are

proposed for immunocompromised patients only. Conclusions. @nbsp;

These revised definitions of invasive fungal disease are intended to

advance clinical and epidemiological research and may serve as a

useful model for defining other infections in high-risk patients.

Other papers by authors: